Navigation Links
/C O R R E C T I O N -- Rosetta Genomics Ltd/
Date:5/21/2008

ess highlights.

The 2008 first-quarter net loss of $3.9 million (including a non-cash expense of $191,000 related to stock based compensation), or $0.33 per ordinary share. The first-quarter result compares with a net loss of $2 million (including a non-cash expense of $205,000 related to stock based compensation), or $0.23 per ordinary share, for the corresponding quarter of 2007.

"This has been a remarkable quarter for us at Rosetta Genomics on both the business and scientific fronts," said Amir Avniel, President and CEO of Rosetta Genomics. "We have continued the rapid advancements towards the launch of the first diagnostic tests based on our microRNA technology, and look forward to the exciting events that lay ahead of us in the following months."

On the business front, Rosetta Genomics recently announced that Columbia University Medical Center's Molecular Pathology Laboratory has submitted the first microRNA-based test based on the company's microRNA technology for regulatory approval to the New York State Department of Health. The test is designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) and is the first of three tests the company expects will be submitted for regulatory approval by CLIA certified labs in 2008.

In addition, the company recently announced an agreement with the University of California, Irvine School of Medicine to develop diagnostic tests based on Rosetta's proprietary microRNA technology.

On the scientific front, in a paper published in the April issue of Nature Biotechnology, Rosetta Genomics and collaborators demonstrated the significant potential of microRNAs to be used as biomarkers for diagnosing the primary tumor site in patients with cancer of unknown primary (CUP). The company expects a CUP test based on its microRNA technology to be submitted for regulatory approval by a CLIA certified lab by the end of 2008.

Financial Overview

Operating loss for th
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... the ultimate memory device for computing may have just ... College of New York led by chemist Stephen O,Brien ... and ferroelectric properties. , Combining both properties is very ... them and for the devices that might ultimately be ... properties in a single material, however, has proved difficult ...
(Date:9/17/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) was ... Young LLP ("EY") that it was resigning effective September 11, ... the Company on September 15, 2014 and reported in PDL,s ... PDL has issued the following statement in response to the ... on the reason for the resignation of EY.  We were ...
(Date:9/17/2014)... DIEGO and PRINCETON, N.J. ... (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic devices ... and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed ... 2014 Exosomes & SingleCell Analysis Summit. On ... Exosome Sciences will give a presentation entitled: "Exosomes: A ...
(Date:9/17/2014)... NEWTOWN, Pa. , Sept. 17, 2014 ... services and eClinical Solutions, today announced three of its ... Conference for Clinical Data Management to be held ... Vegas, Nevada . The Company also announced the ... to raise overall quality in clinical trials acquired earlier ...
Breaking Biology Technology:Oxides discovered by CCNY team could advance memory devices 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... in Medical Imaging Management , For Hospitals, Clinics ... 4 Optimal Reading Services Group, Inc., a US-based, ... imaging centers and radiology groups, announced today that the ... investment in Optimal. The investment provides Optimal with funds ...
... LAVAL, QC, June 4 /PRNewswire-FirstCall/ - Neptune Technologies & ... it has signed an agreement with Bayer Healthcare, LLC ... United States. , "The signing of this agreement with ... business and scientific choice to pursue the more demanding ...
... Reported by Roche at 69th Scientific Sessions , ... (Nasdaq: VIAP ), a biotechnology company focused ... cardiovascular and metabolic disease, announced today that preclinical data ... will be presented in a poster presentation at the ...
Cached Biology Technology:Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 2Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 3Neptune Products to be commercialized by BAYER HealthCare 2Neptune Products to be commercialized by BAYER HealthCare 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4
(Date:9/17/2014)... at UTSouthwestern Medical Center have found that the most ... apoE3, helps repair the lining of blood vessels. Individuals ... benefit of this repair, putting them at higher risk ... identified one mechanism by which apoE3 promotes a healthy ... detrimental," said Dr. Philip Shaul , Professor of ...
(Date:9/17/2014)... social behavior by studying nonhuman mammals and primates, but ... their unusually large brains relative to their body size ... environment---not merely in a large population of cooperating creatures, ... setting of alliances and competitors. The same is true ... social carnivores, like hyenas and lions. , A new ...
(Date:9/16/2014)... (17 September, 2014)More than $100 trillion in cumulative ... annual carbon dioxide (CO2)a 40 percent reduction of ... if the world expands public transportation, walking and ... released by the University of California, Davis, and ... , Further, an estimated 1.4 million early ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Being social: Learning from the behavior of birds 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... While researching methods to increase the already well-recognized ... Illinois also found a way to prolong the vegetable,s ... study, the method is a natural and inexpensive way ... and won,t spoil so quickly on your refrigerator shelf. ...
... disease is the most common form of birth defect, ... the National Institutes of Health. Researchers from the University ... treat laboratory mice with one form of congenital heart ... caused by abnormally thick muscle. By suppressing a faulty ...
... vegetables are associated with higher Body Mass Index (BMI) ... to American University researchers in the journal Pediatric ... between the prices of fruit and vegetables and higher ... and assistant professor of public administration and policy at ...
Cached Biology News:Better broccoli, enhanced anti-cancer benefits with longer shelf life 2Better broccoli, enhanced anti-cancer benefits with longer shelf life 3Compound improves cardiac function in mice with genetic heart defect, MU study finds 2High cost of fruits, vegetables linked to higher body fat in young children 2
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: